News & Events Archive

2017

  • December 21, 2017Suven Life Sciences secures Product Patents in Canada and IndiaView PDF
  • December 11, 2017B&K's Investor Conference Emergent India-2017View PDF
  • December 11, 2017Suven Life Sciences secures Product Patents in India and USAView PDF
  • December 06, 2017Suven Life Sciences secures Product Patents in Eurasia and NorwayView PDF
  • November 16, 2017Suven Life secures Product Patents in HongKong, India and USAView PDF
  • November 13, 2017Suven Life sciences presenting at Neuroscience 2017 at Washington DCView PDF
  • November 11, 2017Suven Income at INR 2586 Mn; PAT at INR 613 Mn for the half year ended September 2017View PDF
  • October 18, 2017Suven Life Sciences secures a Product Patent in SingaporeView PDF
  • October 13, 2017Intimation of sad Demise of Director Dr. K.V. RaghavanView PDF
  • October 10, 2017Suven Life Sciences secures a Product Patent in New ZealandView PDF
  • September 25, 2017Suven Life Sciences secures Product Patents in India and JapanView PDF
  • August 21, 2017Suven Life secures a Product Patent in JapanView PDF
  • August 17, 2017Suven Life secures Process Patents in Europe, Japan and New ZealandView PDF
  • August 14, 2017Suven’s Income at Rs. 1466 Mn; PAT at Rs. 295 Mn for the quarter ended June 2017View PDF
  • July 21, 2017Suven Life secures a Product Patent in AustraliaView PDF
  • July 14, 2017Suven at Alzheimer's Association International Conference (AAIC) in LondonView PDF
  • July 10, 2017Suven Life secures Product Patents in Israel, Macau and South KoreaView PDF
  • June 13, 2017Suven Life secures a Product Patent in Australia and USAView PDF
  • June 03, 2017Suven Team is participating in B&K's Annual Conference 'Trinity India 2017' on June 5, 2017 - MumbaiView PDF
  • May 30, 2017Annual Investor Conference "Centrum Corporate Connect - 2017 with fund managers and analysts meet orView PDF
  • May 25, 2017Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a NView PDF
  • May 13, 2017Suven Revenue up by 9%; PAT up by 23% for the year ended March 2017View PDF
  • May 11, 2017Q4FY17 Schedule of conference call for InvestorsView PDF
  • March 28, 2017Suven Life secures a Product Patents in New ZealandView PDF
  • February 03, 2017Suven Team is participating in "ICICI Securities’ Annual Investor Conference 2017" on 6th – 7th FebrView PDF
  • February 02, 2017Q3FY17 Earnings Conference Call TranscriptView PDF
  • February 01, 2017Suven Revenue up by 9.98%; PAT up by 32.77% for 9 months ended December 2016View PDF
  • January 30, 2017Q3FY17 Schedule of Conference Call for InvestorsView PDF
  • January 30, 2017Suven Life Sciences secures a Product Patent in USAView PDF
  • January 23, 2017Suven Life Sciences secures a Product Patent in AustraliaView PDF
  • January 11, 2017SuvenInc is presenting at Biotech Showcase™ 2017 on 11th January and attending 35th Annual J.P. MorgView PDF
  • January 03, 2017Suven Life Sciences secures two (2) Product Patents in Eurasia and NorwayView PDF

2016

  • December 08, 2016Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE(CTAD) Conference held during DecemberView PDF
  • December 07, 2016Suven Life Sciences secures one (1) Product Patent in IndiaView PDF
  • November 25, 2016Q2FY17 Earnings Conference Call TranscriptView PDF
  • November 24, 2016Suven Revenue growth at 13.42%; PAT up by 29.15% for the half year ended Sept, 2016View PDF
  • November 22, 2016Q2FY17 Schedule of Conference Call for InvestorsView PDF
  • November 22, 2016Suven Life Sciences secures two (2) Product Patents in China and MexicoView PDF
  • November 15, 2016Suven Life Sciences is participating and presenting in “Jefferies London Healthcare Conference “, LoView PDF
  • November 14, 2016Suven Life Sciences presenting at Society for Neuroscience (SFN-2016) San Diego.View PDF
  • October 18, 2016Suven Life Sciences secures two (2) Product Patents in Europe and IsraelView PDF
  • September 26, 2016Suven Life Sciences secures two (2) Product Patents in India and JapanView PDF
  • September 08, 2016Suven Life secures three (3) Product Patents in Canada, Europe and Hong KongView PDF
  • August 11, 2016Q1FY17 Earnings Conference Call TranscriptView PDF
  • August 10, 2016Q1FY17 Schedule of Conference Call for InvestorsView PDF
  • August 10, 2016Suven’s Income at Rs. 1377 Mn; PAT at Rs. 326 Mn for the 1st quarter ended June 2016View PDF
  • August 01, 2016Suven Life secures two (2) Product Patents in Macau and New ZealandView PDF
  • July 25, 2016Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
  • July 21, 2016SUVEN’S Pashamylaram’s Unit Successfully completes US FDA InspectionView PDF
  • July 12, 2016Suven Life secures two (2) Product Patents in India and South AfricaView PDF
  • June 29, 2016Suven Life secures three (3) Product Patents in Europe and EurasiaView PDF
  • June 14, 2016Suven Life Sciences secures two (2) Product Patents in Canada and Hong KongView PDF
  • June 03, 2016Suven Life Sciences secures two (2) Product Patents in Israel and MexicoView PDF
  • May 31, 2016Suven Team is participating in "Annual Investors Conference Trinity India-2016" on June 1stView PDF
  • May 30, 2016Q4FY16 Earnings Conference Call TranscriptView PDF
  • May 30, 2016Q4FY16 Schedule of Conference Call for InvestorsView PDF
  • May 27, 2016Suven Revenue up by 49.21%; PAT up by 83.23% for the Fourth quarter ended March 2016View PDF
  • May 23, 2016Suven Life Sciences secures 4 (four) Product Patents for their NCE's in Australia, Eurasia, Israel aView PDF
  • April 04, 2016Suven to Present at Bio-Europe Spring 2016 conference being held at Stockholm, Sweden.View PDF
  • March 14, 2016Suven Life secures three (3) Product Patents in China, Eurasia and Hong KongView PDF
  • March 09, 2016Investors Meet on 10th & 11th March, 2016View PDF
  • March 07, 2016Investor Conference Call on 8th March, 2016View PDF
  • February 19, 2016Suven Life Sciences secures two (2) Product Patents in Australia and CanadaView PDF
  • February 15, 2016Q3FY16 Earnings Conference Call TranscriptView PDF
  • February 12, 2016Suven Revenue down by 4.96%; PAT down by 28.34% for the Third quarter ended December, 2015View PDF
  • January 11, 2016Suven Inc is presenting at Biotech Showcase™ 2016 and participating in the 34th Annual J.P. Morgan HView PDF
  • January 05, 2016Suven Life Sciences secures three (3) Product Patents in Canada, ARIPO and South KoreaView PDF

2015

  • December 29, 2015Suven Life Sciences secures Two (2) Product Patents in Europe and MacauView PDF
  • December 23, 2015Suven Life Sciences secures 7 (seven) Product Patents for their NCE’s in ARIPO, Europe, Hong Kong, JView PDF
  • December 14, 2015Suven Life Sciences at Centrum Pharma Day Mumbai for analysts’ meetView PDF
  • December 11, 2015Suven Life secures four (4) Product Patents in Eurasia, Europe, Israel and MacauView PDF
  • December 07, 2015Suven Initiates Phase 2A trial of SUVN-502 in USA in Alzheimer’s DiseaseView PDF
  • November 16, 2015Q2FY16 Earnings Conference Call TranscriptView PDF
  • November 10, 2015Suven Revenue growth at 15.55%; PAT up by 22.23% for the Second quarter ended Sept, 2015View PDF
  • November 05, 2015Suven to Present at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during NOVEMBEView PDF
  • November 02, 2015Suven to Present at Bio-Europe 2015 Partnering conference held during November 2 - 4, 2015 in MunichView PDF
  • October 19, 2015Suven Life Sciences at Society for Neuroscience (SFN-2015) Chicago. Presenting data on several of thView PDF
  • October 13, 2015Suven Life Sciences secures 5 (five) Product Patents for their NCE’s in Australia, China, Europe, SoView PDF
  • September 28, 2015Suven Life secures three (3) Product Patents in New Zealand, Singapore and USAView PDF
  • September 16, 2015Suven Life Sciences secures Three (3) Product Patents in Canada and ChinaView PDF
  • September 10, 2015Suven Life Sciences secures five (5) Product Patents in China, Israel, Mexico, Singapore and Sri LanView PDF
  • September 02, 2015SUVN-D4010 for Cognition in Alzheimer’s disease commenced Phase 1 Clinical Trial in USA under US-INDView PDF
  • August 17, 2015Q1FY16 Earnings Conference Call TranscriptView PDF
  • August 14, 2015Suven’s Income lower by 7.35%; PAT increase by 19.36% for the quarter ended June 2015View PDF
  • July 17, 2015Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
  • July 13, 2015Suven Life Sciences secures 4 (four) Product Patents for their NCE’s in China, Mexico and South AfriView PDF
  • June 30, 2015Suven Life Sciences secures Three (3) Product Patents in Israel, Japan and South AfricaView PDF
  • June 16, 2015Suven Life secures Three (3) Product Patents in Israel, Macau and USAView PDF
  • May 27, 2015Q4 FY15 Conference Call TranscriptView PDF
  • May 26, 2015Suven’s Income increased by 3% and PAT lower by 25% for the year ended March 2015View PDF
  • May 22, 2015Suven Life secures One (1) Product Patent each in Mexico and SingaporeView PDF
  • May 13, 2015Suven Life secures Two (2) Product Patents in Europe and Hong kongView PDF
  • April 24, 2015Suven Life secures Five (5) Product Patents for their NCEs in Australia, Europe, Hong kong, Israel aView PDF
  • April 13, 2015Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigatView PDF
  • March 24, 2015Suven Life secures Three (3) Product Patents for their NCEs in Canada, Japan and KoreaView PDF
  • March 16, 2015Suven Life Sciences secures 2 (two) Product Patents for their NCE’s through New mechanism of actionView PDF
  • March 09, 2015Suven Life secures One (1) Product Patent each in Eurasia and IsraelView PDF
  • February 16, 2015Suven Life Sciences secures 4 (four) Product Patents for their NCE’s through New mechanism of actionView PDF
  • February 13, 2015Q3 FY15 Conference Call TranscriptView PDF
  • February 10, 2015Suven Revenue growth at 9% while PAT is down by 11.55% for the 3rd Quarter ended Dec 2014View PDF
  • January 20, 2015Suven Life secures One (1) Product Patent each in Australia & Hong Kong, two (2) product patents froView PDF

2014

  • December 30, 2014Suven Life secures three (3) Product Patents in Eurasia, Japan, and MexicoView PDF
  • December 30, 2014Suven Life secures three (3) Product Patents in Eurasia, Japan, and MexicoView PDF
  • December 12, 2014Suven Life secures (5) Product Patents for their NCEs in Israel, Japan, China and New ZealandView PDF
  • December 03, 2014Suven Life Sciences Limited Raises INR 200 Cr Through a Qualified Institutions Placement (QIP)View PDF
  • November 17, 2014Q2 FY15 Conference Call TranscriptView PDF
  • November 14, 2014Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended Sept, 2014View PDF
  • November 03, 2014SUVN-G3031 for Cognition in Alzheimer’s Disease commenced Phase 1 Clinical Trial in USA under US-INDView PDF
  • October 13, 2014Suven Life secures One (1) Product Patent in South Korea and one (1) from USAView PDF
  • October 07, 2014Suven Life Sciences is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.View PDF
  • September 23, 2014Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export PerformaView PDF
  • September 03, 2014Suven Life Sciences secures (3) Product Patents for their NCEs in South Korea, China and CanadaView PDF
  • August 12, 2014Suven achieved a PAT of Rs.34.73 Crores for first Qtr of 2014-15, an increase of 16.68% compared toView PDF
  • August 06, 2014Suven Life secures (2) Product Patents for their NCEs in Australia and EurasiaView PDF
  • July 11, 2014Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
  • June 04, 2014Suven Life secures One (1) Product Patent in USAView PDF
  • May 26, 2014Suven Investor/Analyst Conference Call TranscriptView PDF
  • May 22, 2014Suven’s PAT up by 367% for the year ended March 2014 & proposed regular and one time special silverView PDF
  • May 19, 2014Suven Life secures (3) Product Patents in Australia, South Korea and ChinaView PDF
  • April 10, 2014Suven Life secures (2) Product Patents for their NCEs in Canada and Hong KongView PDF
  • April 03, 2014Suven Life Sciences secures 4 Product Patents for their NCEs in China and KoreaView PDF
  • March 26, 2014Suven Life secures (2) Product Patents for their NCEs in USAView PDF
  • March 04, 2014Suven grants an exclusive license & right to distribute its Malathion Lotion in USA, CANADA and MEXIView PDF
  • February 14, 2014Suven Life secures (2) Product Patents for their NCEs in New ZealandView PDF
  • February 06, 2014Suven Investor/Analyst Conference Call TranscriptView PDF
  • February 04, 2014Suven Q3 PAT up by 370% to Rs.36.43 CrView PDF
  • January 31, 2014Suven Life secures (3) Product Patents for their NCEs in Canada, China and IndiaView PDF
  • January 22, 2014SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCEView PDF
  • January 09, 2014Suven Life secures three (3) Product Patents for their NCEs in Australia, Sri Lanka and South KoreaView PDF

2013

  • November 13, 2013Suven Investor/Analyst Conference Call TranscriptView PDF
  • November 11, 2013Suven Q2 PAT up by 602% to Rs.45.55 CrView PDF
  • November 08, 2013Suven Life Sciences presenting the positive pharmacology data of 4 NCEs at Society for NeuroscienceView PDF
  • September 25, 2013Suven Life secures three (3) Product Patents for their NCEs in New Zealand, Singapore and South KoreView PDF
  • August 13, 2013Suven Q1 PAT up by 274% to Rs.29.77 CrView PDF
  • August 08, 2013Suven Life secures two (2) Product Patents for their NCEs in EuropeView PDF
  • July 12, 2013Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
  • July 05, 2013Suven Life secures two (2) Product Patents for their NCEs in USA and JapanView PDF
  • June 28, 2013Suven Life Sciences secures two (2) Product Patents for their NCEs in Japan and USAView PDF
  • May 14, 2013Suven‘s PAT up by 115% for the year ended Mar 2013View PDF
  • May 10, 2013Suven Life Sciences secures three Product Patents for their NCEs in Canada and Eurasia.View PDF
  • April 17, 2013Suven Life Sciences secures 4 Product Patents for their NCEs in China, Mexico and New ZealandView PDF
  • February 12, 2013Suven‘s PAT up by 500 % for the quater ended Dec 2012View PDF

2012

  • December 31, 2012Suven Life Sciences secures 3 Product Patents for their NCEs in Eurasia & Canada.View PDF
  • December 13, 2012Suven Life Sciences secures 5 Product Patents for their NCEs in China & KoreaView PDF
  • November 15, 2012Suven‘s PAT up by 153% for the quarter ended 30th September’ 2012View PDF
  • October 04, 2012Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”View PDF
  • August 14, 2012Suven‘s PAT up by 137 % & Turnover up by 58 % for 1st Quarter ended 30th June 2012View PDF
  • August 09, 2012Suven Life Sciences secures 4 Product Patents for their NCEs in Australia, Canada, Korea and New ZeaView PDF
  • July 13, 2012Suven to Present at Alzheimer's Association International Conference (AAIC)View PDF
  • May 22, 2012Suven Life Sciences secures 4 Product Patents for their NCEs in Japan, Australia, Europe and EurasiaView PDF
  • May 04, 2012Suven‘s PAT up by 137% for 4th Quarter ended 31st Mar’2012View PDF
  • February 07, 2012Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USAView PDF
  • January 31, 2012Suven‘s revenue up by 57% and EBIDTA up by 168% for 3rd Quarter ended 31st Dec’2011View PDF
  • January 11, 2012Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011View PDF

2011

  • December 08, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and CanadaView PDF
  • November 14, 2011Suven Life Sciences presenting the Pre-clinical data of their NCEs at Society for Neuroscience (SFN-View PDF
  • November 01, 2011Suven‘s revenue up by 31% and spends 18% of revenue on R&D;View PDF
  • October 04, 2011Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”View PDF
  • September 22, 2011Suven Participating at 4th CNS Partnering & Deal Making Conference in USAView PDF
  • September 05, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in Australia and New ZealandView PDF
  • August 18, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in the key markets in the worldView PDF
  • August 13, 2011Suven‘s revenue up by 24% and spends 17% of revenue on R&DView PDF
  • July 18, 2011Suven presenting at International Conference on Alzheimer’s disease (ICAD)View PDF
  • June 20, 2011Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the worldView PDF
  • May 30, 2011Suven Spends 20.5% of Revenue on R&D PAT up by 48.55% for the year ending March 2011View PDF
  • May 26, 2011Suven Life Sciences secures 4 Product Patents for their NCEs in several key markets in the worldView PDF
  • May 18, 2011Suven’s Alzheimer drug candidate SUVN-502 successfully completed all chronic toxicological (tox) stuView PDF
  • May 09, 2011Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”View PDF
  • April 26, 2011Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the worldView PDF
  • April 05, 2011SUVEN’S UNIT-III RECEIVES US FDA ACCEPTANCEView PDF
  • January 31, 2011Suven spends 24% of revenue on R&D ;PAT up by 55% for for the 3rd quarter ending Dec 2010View PDF

2010

  • December 30, 2010Suven Life Sciences secures 2 Product Patents For Their NCEsView PDF
  • December 23, 2010Suven Life Sciences secures 4 Product Patents For Their NCEsView PDF
  • November 12, 2010Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual MeView PDF
  • October 27, 2010Suven spends 21% of revenue on R&D PAT up by 23% for the half yearView PDF
  • September 27, 2010Suven Life Sciences bags Pharmexcil's Gold “Patent Award”View PDF
  • September 21, 2010Suven Life Sciences secures Two US Patents on NCEsView PDF
  • September 08, 2010Suven Secures 8th product patent Both in Australia and MexicoView PDF
  • July 27, 2010Suven spends 22% of revenue on R&D PAT up by 58% for the 1st QuarterView PDF
  • July 12, 2010Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)View PDF
  • June 16, 2010Suven Life Sciences secures Two (2) Product Patents from Japanese Patent Office (JPO) for their NCE’View PDF
  • May 25, 2010Suven’s partnering and fundraising activity at C21 BioVentures™View PDF
  • May 12, 2010Suven Life Sciences secures 3rd Canadian and 6th Eurasian Patent for their NCEView PDF
  • May 03, 2010Prof. Syed Hasnain joins Suven as Additional DirectorView PDF
  • April 30, 2010Suven spends 26% of Revenue on R&D for the year ended March 2010View PDF
  • April 28, 2010Suven Life Sciences secures Product Patents from India and New ZealandView PDF
  • April 22, 2010Suven Life Sciences secures Three Australian Patents on NCEsView PDF
  • April 12, 2010Suven Life Sciences secures First Product Patent from Japanese Patent Office (JPO) for their NCE toView PDF
  • March 29, 2010Suven Life Sciences secures 8th Product Patent from European Patent Office (EPO) for their NCE to trView PDF
  • March 22, 2010Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat CentralView PDF
  • January 27, 2010Suven spends 34% of Revenue on R&D for the 3rd quarter ending Dec’ 09View PDF
  • January 12, 2010Suven Secures Two product patents in China and RussiaView PDF

2009

  • December 14, 2009Suven Secures two Product patents from Canadian Intellectual Property OfficeView PDF
  • November 30, 2009Suven Life Sciences secures Three European Patents on NCEsView PDF
  • October 31, 2009Suven spends 29.78% of Revenue on R&D for the quarter ending Sep 09View PDF
  • October 20, 2009Suven Life Sciences presenting Pre-clinical data of their NCEs at Society for Neuroscience Annual MeView PDF
  • October 14, 2009Suven’s Clinical Candidate SUVN-502 For Alzheimer’s disease Secures product patents in several Key mView PDF
  • September 14, 2009Suven Life Sciences secures Two US Patents on NCEsView PDF
  • September 07, 2009Suven achieves 1st Milestone payment in Drug Discovery collaborationView PDF
  • July 28, 2009Suven’s profit up by 37%, Spends 22% of Revenue on R&D.View PDF
  • July 27, 2009Suven Presented Positive Phase-I clinical data of SUVN-502 for Alzheimer’s disease at ICAD 2009, VieView PDF
  • May 06, 2009SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.View PDF
  • April 29, 2009Suven’s revenue up by 19%, Spends 22% of Revenue on R&D.View PDF
  • April 09, 2009Suven completes Phase I Clinical Trials Multiple Ascending Dose of SUVN-502 in Switzerland.View PDF
  • January 19, 2009Suven’s revenue up by 21%, Spends 24% of Revenue on R&D.View PDF
  • January 13, 2009Suven participation at Biotech Showcase 2009.View PDF

2008

  • November 18, 2008Suven participation at Bio-Europe 2008.View PDF
  • November 11, 2008Suven Presentation at Rodman & Renshaw 10th Annual Healthcare Conference at New York being held fromView PDF
  • October 31, 2008Suven's net up by 50%, Spends 17% of Revenue on R&DView PDF
  • October 13, 2008SUVN-502 data being presented at 16th BioPartnering in LondonView PDF
  • September 29, 2008Suven completed Phase-I Clinical Trials Single Ascending Dose of SUVN-502 in SwitzerlandView PDF
  • September 25, 2008DCGI nod to conduct Phase-I Clinical Trials of SUVN-502 for Alzheimer’s diseaseView PDF
  • August 18, 2008Suven granted Certificate of Suitability (CEP) for Tamsulosin HydrochlorideView PDF
  • August 04, 2008Suven Life Sciences Presents Positive Preclinical Data for SUVN-502 at Alzheimer’s conference, ChicaView PDF
  • July 25, 2008Revenue growth for quarter at 11.43%, Commences Phase 1 clinical trial of SUVN-502 in Switzerland foView PDF
  • July 07, 2008Suven Life Sciences Clinical candidate SUVN-502 being presented at International Conference on AlzheView PDF
  • June 18, 2008Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s diseaseView PDF
  • May 27, 2008Suven Life Sciences gets Two product patents for NCEs in Russia and AustraliaView PDF
  • May 27, 2008Suven Life Sciences gets Two product patents for NCEs in Russia and AustraliaView PDF
  • May 20, 2008Suven Life Sciences gets Two product patents for NCEs in South Africa and ChinaView PDF
  • May 05, 2008Suven's Clinical Candidate SUVN-502 Secures European Product PatentView PDF
  • March 31, 2008Suven Life Sciences gets Two Product patents in Korea and MexicoView PDF
  • March 24, 2008Suven Life Sciences secures Two product Patents in all Russian countries (Eurasia Region)View PDF
  • March 12, 2008Suven Establishes second CNS Drug Discovery Collaboration with LillyView PDF
  • January 28, 2008Suven Revenue stands flat, R&D spent at 25% of Revenue obtains 2 US, 3 European and 4 Indian ProductView PDF
  • January 23, 2008Suven obtains  2nd Product Patent from US Patent officeView PDF

2007

  • December 27, 2007Suven obtains 1st Product Patent from US Patent officeView PDF
  • December 11, 2007Suven presenting at Windhover's Bio/Pharma Partnerships conference in San FranciscoView PDF
  • November 27, 2007Suven Life Sciences secures two Product Patents from European Patent Office (EPO) for the treatmentView PDF
  • November 05, 2007-Suven Life Sciences presenting Pre-clinical data of their NCE's at Society for Neuroscience AnnualView PDF
  • October 31, 2007Suven Life Sciences secures Two (2) Product Patents in Australia & New Zealand for their New ChemicaView PDF
  • October 30, 2007Suven's half yearly revenues increase by 10%, R&D spent at 26% of RevenueView PDF
  • October 25, 2007Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infectionView PDF
  • October 23, 2007Suven Life Sciences Secures Three (3) Indian Product Patents For Their New Chemical Entities (NCEs)View PDF
  • July 31, 2007Suven PAT up by 51%;R&D spend at 33% of RevenueView PDF
  • July 12, 2007Suven Life Sciences files its first Investigational New Drug (IND) application of its NCE SUVN-502 iView PDF
  • July 05, 2007Suven Life Sciences presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507 at InternationView PDF
  • June 11, 2007-Suven's unit III receives US FDA acceptanceView PDF
  • April 26, 2007Suven yearly revenues increase by 38%, PAT up by 33% ; R&D spend at 24% of RevenueView PDF
  • January 29, 2007Suven Income up by 35%, Spends 17% on R&D -Suven shares split from Rs 2 per share to Re. 1 per shareView PDF
  • January 01, 2007Suven renewed ISO 14001 certificationView PDF
  • January 01, 2007Suven renewed ISO 9001 certificationView PDF
  • January 01, 2007Suven received OHSAS 18001 certificationView PDF

2006

  • September 20, 2006Suven receives NABL certificationView PDF
  • August 29, 2006Suven and Lilly Establish Drug Discovery CollaborationView PDF
  • August 16, 2006Preclinical Data on Suven’s 5-HT6 antagonists for CNS diseases to be presented at Neuroscience 2006View PDF
  • July 31, 2006SUVEN’s quarterly revenues increase by 60%, PAT up by 51%; R&D spend at 16% of RevenueView PDF

2005

  • November 21, 2005Suven Life Sciences presented Pre-clinical data of their NCEs at Society for Neuroscience (SFN) AnnuView PDF
  • October 11, 2005Suven Awarded Phase III Clinical study for Chronic Low Back pain.View PDF
  • October 03, 2005Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & SullivanView PDF

2004

  • December 14, 2004Suven Life Sciences ropes in global contract research industry veteranView PDF
  • October 12, 2004Suven pharma promoter invests $1-m in CRO, data developmentView PDF
  • April 27, 2004Suven Life income up 10 p.c.View PDF
  • April 23, 2004Suven Life Sciences net Income up by 27.76%View PDF
  • March 24, 2004Suven to set up Rs 100 cr unit in VizagView PDF
  • February 05, 2004Suven Life Sciences net up 57 percentView PDF
  • February 01, 2004Suven profit up 5% to Rs. 1.91 cr in Q3View PDF
  • January 01, 2004Suven gets ISO 14001 certificationView PDF

2003

  • December 18, 2003Suven Life to raise Rs 27.4 cr through preferential issue Borregaard exits Suven Life SciencesView PDF
  • December 05, 2003Suven board okays merger of subsidiary Suven Life board decides to split sharesView PDF
  • November 28, 2003Suven board to consider merger of subsidiarySuven Life Sciences may merge arm with selfSuven plans pView PDF
  • November 24, 2003Suven graduating itself to life sciences playerView PDF
  • October 23, 2003The $15 billion bulk drug opportunityCPhI: Downpour of dealsView PDF
  • September 29, 2003Venkat Jasti re-elected president of BDMAView PDF
  • September 06, 2003Spurious drugs eating into AP’s export shareView PDF
  • August 07, 2003Suven Pharma rechristened Suven LifeView PDF
  • August 02, 2003Suven Pharma is Suven Life nowView PDF
  • August 01, 2003Suven Q1 net up 63% at Rs 2.3 crView PDF
  • July 07, 2003PA fellowship AwardView PDF
  • June 12, 2003Venkat Jasti asks Govt. & Industry to play pro-active role to tap the potential post-2005View PDF
  • June 02, 2003Venkat Jasti joins Pharmabiz advisory boardView PDF
  • May 20, 2003SUVEN Pharma acquires assets of New Jersey (USA) based SYNTHON CHIRAGENICSView PDF
  • April 26, 2003SUVEN spent 21 % of its revenue in R & DView PDF
  • April 21, 2003SUVEN eyes discovery researchView PDF
  • March 25, 2003Drug discovery boutique set up 3 Indian Pharma form allianceDesi Pharma trio ally for new patent regView PDF

2002

  • December 24, 2002SUVEN Pharma sees revenue jump after April 2004View PDF
  • October 18, 2002SUVEN starts research academySUVEN Pharma to collaborate in promoting the Centre of Excellence in clView PDF
  • August 07, 2002SUVEN sets the stage for Contract Research in IndiaView PDF
  • June 03, 2002Speeding up drug discoveryView PDF

2001

  • December 25, 2001Pharma sector hopes to have Export Promotion Council soon Andhra Pradesh to set up Pharma CityView PDF
  • December 24, 2001After IT and BT, Pharma catches Chandrababu Naidu's eyeForget IT, Pharma is the new mantraPharmaexciView PDF
  • December 23, 2001Pharma City in VizagView PDF
  • December 21, 2001Vizag's Pharma City to get a booster doseVizag Pharma City Phase-I to be operational by 2003View PDF
  • November 23, 2001A.P. to attract global majors as healthcare capitalView PDF
  • November 01, 2001SUVEN PharmaView PDF
Back